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Objectives. This study was designed to determine 1) whether
12-week oral administration of losartan, an angiotensin II recep-
tor antagonist, in patients with heart failure is well tolerated; and
2) whether functional capacity and clinical status of patients with
heart failure in whom treatment with an angiotensin-converting
enzyme (ACE) inhibitor is replaced with losartan for 12 weeks will
remain similar to that noted in patients in whom treatment with
an ACE inhibitor is continued.
Background. Losartan is a specific, nonpeptide angiotensin II
receptor antagonist. Although specific receptor blockade with
losartan has certain theoretic advantages over nonspecific ACE
inhibition, definitive demonstration of comparable effects in pa-
tients with congestive heart failure is lacking.
Methods. A double-blind, multicenter, randomized, parallel,
enalapril-controlled study was conducted in 116 patients with
congestive heart failure (New York Heart Association functional
classes II to IV) and left ventricular ejection fraction <245%
previously treated with stable doses of ACE inhibitors and di-
uretic agents, with or without concurrent digitalis and other
vasodilators. After a baseline exercise period, open-label ACE
inhibitors were discontinued, and patients were randomly as-
signed to 12 weeks of therapy with losartan, 25 mg/day (n 5 38);
losartan, 50 mg/day (n 5 40); or enalapril, 20 mg/day (n 5 38).
Drug efficacy was evaluated by changes in maximal treadmill
exercise time (using a modified Naughton protocol), 6-min walk
test, left ventricular ejection fraction and dyspnea-fatigue index.
Safety was measured by the incidence of clinical and laboratory
adverse experiences.
Results. The treadmill exercise time and the 6-min walk test did
not change significantly after replacement of ACE inhibitor
therapy with losartan. Similarly, a significant change was not
observed in either the dyspnea-fatigue index or left ventricular
ejection fraction at the end of double-blind period relative to
baseline.
Conclusions. Losartan was generally well tolerated and compa-
rable to enalapril in terms of exercise tolerance in this short-term
(12-week) study of patients with heart failure. The clinical effects
of long-term angiotensin II receptor blockade compared with ACE
inhibition remain to be studied.
(J Am Coll Cardiol 1997;30:983–91)
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Pharmacologic blockade of the renin-angiotensin-aldosterone
system (RAAS) with angiotensin-converting enzyme (ACE)
inhibitors in patients with symptomatic heart failure or asymp-
tomatic left ventricular dysfunction results in clinical benefits
such as symptomatic relief of dyspnea, improvement in left
ventricular function, prevention of progressive ventricular di-
lation, decreased need for hospitalization and improved sur-
vival (1–6).
Recently, hemodynamic benefits accompanied by favorable
clinical responses have been reported using an alternative
method of inhibition of the RAAS with the angiotensin II
receptor antagonist losartan (7–11). Specific blockade of the
angiotensin II receptor has certain theoretic advantages over
nonspecific ACE inhibition (12). For example, losartan does
not block the degradation of vasoactive substances such as
bradykinin, enkephalins and substance P, and may not cause
side effects such as cough related to ACE inhibitor–induced
bradykinin accumulation. In addition, specific angiotensin II
receptor blockade could block the deleterious effects of angio-
tensin II produced not only through the classic pathway
involving ACE but also by nonconverting enzyme-dependent
pathways, which are not blocked by ACE inhibitors, within
cardiac myocites and arterial wall tissues. For these reasons,
blockade of the actions of angiotensin II at the receptor level
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may constitute an attractive pharmacologic alternative for all
patients with heart failure, not just for patients intolerant to
the side effects of ACE inhibitors (13–15). Before long-term
clinical studies using losartan can be initiated, additional
information on its safety profile and effectiveness are required.
Accordingly, this study was designed to determine 1) whether
12-week oral administration of losartan to patients with heart
failure is well tolerated; and 2) whether the functional capacity
and clinical status of patients with heart failure in whom
treatment with an ACE inhibitor is replaced with losartan for
12 weeks will remain similar to that noted in patients in whom
treatment with the ACE inhibitor is continued.
Methods
Study design. This study was a multicenter (16 centers—15
from the United States and 1 from Canada), double-blind,
randomized, parallel, enalapril-controlled study performed in
116 patients with symptomatic heart failure (New York Heart
Association functional classes II to IV) and left ventricular
ejection fraction (LVEF) #45%.
Baseline exercise period: screening and eligibility. Figure 1
depicts the protocol used for data acquisition. At the initial
clinic visit, patients underwent a medical history review, a
complete physical examination, a review of symptoms of heart
failure, a complete laboratory screening, a radionuclide ven-
triculogram, a 12-lead electrocardiogram, a chest x-ray film
and the dyspnea-fatigue index (16). Patients eligible to partic-
ipate in the study must have received stable doses of ACE
inhibitors and diuretic agents for a minimum of 6 and 2 weeks,
respectively, before the first baseline exercise test (visit 2).
Therapy with digoxin or non-ACE inhibitor vasodilators, or
both, was permitted; if receiving digoxin, the patient had to be
treated with digoxin for 6 weeks before the second study visit,
and the dosage had to remain stable for the last 2 weeks; if
receiving non-ACE inhibitor vasodilators, the patient had to be
taking stable doses for 6 weeks before visit 2. Before enroll-
ment all patients signed an informed consent form, which was
previously approved by the Institutional Review Board of each
institution.
Placebo study medication was given to all patients during
the baseline period starting at visit 2. During this period,
patients continued to receive ACE inhibitors. All clinic visits
were conducted in the morning, before the study drug or other
concomitant medications were taken (i.e., at the trough of the
dose interval for all study and nonstudy cardiovascular medi-
cations). At each visit, the patient underwent an abbreviated
physical examination and a review of symptoms. In addition, a
complete laboratory screening and dyspnea-fatigue index were
also performed during visit 4. Three 6-min walk tests, at visits
2, 3, and 4, and two treadmill exercise tests using the modified
Naughton protocol, at visits 2 and 3, were performed during
the baseline exercise period. During these visits, the treadmill
exercise tests were always performed at least 1 h or more after
the 6-min walk test.
Patients were randomized as either a “treadmill” or “non-
treadmill patient”; at least 80% of patients enrolled in each
center had to be treadmill patients. To qualify as a “treadmill
patient,” subjects had to successfully complete two consecutive
baseline treadmill exercise tests in which the exercise duration
did not differ by more than 10% (if the exercise duration was
,10 min for the first test) or 60 s (if the exercise duration was
.10 min for the first test). To satisfy this inclusion criterion,
treadmill tests could be repeated a maximum of five times
during the baseline period. Patients were scheduled with
intervals ranging from 2 days to 2 weeks between exercise tests.
Randomization and double-blind period. Randomization
into the double-blind period occurred within 5 days of com-
pletion of the baseline exercise period. At the time of random-
ization, open-label ACE inhibitor therapy was discontinued.
All other concomitant medications administered during the
baseline exercise period were continued during the double-
blind period. Double-blind study medication was initiated in
the morning before the patient received any other concomitant
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
LVEF 5 left ventricular ejection fraction
RAAS 5 renin-angiotensin-aldosterone system
Figure 1. Protocol and data acqui-
sition. EF 5 ejection fraction;
RNA 5 radionuclide angiography.
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medications. Patients were randomized to receive one of three
active treatments for 12 weeks: 1) losartan, 12.5 mg, titrated as
tolerated to 25 mg every day; 2) losartan, 12.5 mg, titrated as
tolerated to 25 and then 50 mg every day; or 3) enalapril,
2.5 mg, titrated as tolerated to 5 and then 10 mg twice daily.
In all study groups, dosages were increased at 1-week
intervals unless a serious or intolerable adverse experience
occurred.
Evaluation criteria. Efficacy variables included symptom-
limited treadmill exercise duration (6, 11 and 12 weeks after
randomization), 6-min walk test (6, 9 and 12 weeks after
randomization) (17), the dyspnea-fatigue index (6 and 12
weeks after randomization) (16), signs and symptoms of heart
failure and functional class. The average duration of both
qualifying baseline treadmill exercise tests and the average
distance of the final two baseline 6-min walk tests were used as
baseline exercise duration and distance, respectively. The week
12 treadmill exercise duration (in seconds) was calculated as
the average of week 11 and week 12 data when the difference
in days between the two tests was #14 days; if this interval was
larger, only the week 12 measurement was used. Other mea-
surements performed at each study visit are outlined in Figure
1. Safety and tolerability were assessed by the incidence of
clinical and laboratory adverse events.
Statistics. Baseline comparisons. Several statistical meth-
ods were used to compare the three different treatment groups
with respect to the distribution of baseline patient character-
istics. The Fisher exact test was used to compare the treatment
groups with respect to the distribution of nominal demo-
graphic characteristics and race. The Wilcoxon test was used to
compare treatment groups with respect to ordinal categoric
attributes such as functional class. Analysis of variance (based
on ranks) was used to compare treatment groups with respect
to continuous (ordinal) attributes such as walk distance, exer-
cise duration, dyspnea-fatigue index, jugular venous distention
at 45° and ejection fraction.
Efficacy analyses approaches and methods. Analyses were
performed using the baseline and last double-blind measure-
ments. If a patient’s week 12 data were missing, measurements
obtained during the last completed double-blind period were
used for the statistical analysis. Analyses were performed for
both continuous and discrete end points. Intergroup compar-
isons with respect to continuous end points (walk distance,
exercise duration, dyspnea-fatigue index, ejection fraction and
jugular venous distention at 45°) were based on adjusted means
resulting from analysis of covariance performed on the change
from baseline with treatment as a factor, baseline as a covari-
ate and investigator as a blocking variable. With regard to the
discrete end points (exertional dyspnea, paroxysmal nocturnal
dyspnea, orthopnea, edema, rales, third heart sound and
functional class), baseline-adjusted comparisons between the
treatment groups were performed using Cochran-Mantel
Haenszel statistics. Intragroup changes from baseline were
analyzed using the Wilcoxon signed-rank test.
Results
Patient characteristics. Baseline patient demographics and
heart failure characteristics are summarized in Table 1. The
majority of patients were male (78%) and white (71%). The
mean age was 58 6 13 years (range 25 to 83); the mean
duration of the diagnosis of heart failure was 4.4 6 4.8 years
(range 0.33 to 35); and the mean LVEF was 25 6 7%. Most of
the patients were identified as being in functional class II
(47%) or III (51%) and diagnosed with ischemic heart disease
(47%) or dilated cardiomyopathy (41%). There were no
statistically significant differences in the demographics and
heart failure characteristics among the different treatment
groups. The most common therapies used before enrollment
are displayed in Table 2. As noted, all patients were receiving
some type of cardiovascular medications, with 99% of the
patients receiving diuretic agents, 84% digoxin, 43% enalapril
and 37% captopril.
Efficacy. Several criteria were used to assess the efficacy of
treatment with losartan. These included 1) a 6-min walk test; 2)
a modified Naughton treadmill exercise test; 3) the dyspnea-
fatigue index; 4) the LVEF; and 5) signs and symptoms of
heart failure. The effects of treatment assignment on each of
these variables are shown in Table 3.
Six-minute walk test. No intergroup differences in mean
change in distance walked were observed (p 5 0.79).
Modified Naughton treadmill exercise test. No intergroup
differences were noted at baseline. Exercise duration at the
end of the study was increased from baseline for the enalapril
group (p 5 0.03) and marginally increased (p 5 0.06) for the
50-mg losartan group.
Dyspnea-fatigue index. No significant intergroup differences
were detected at baseline (p 5 0.92). At the end of the study,
this index was significantly improved from the baseline value
for the 25-mg losartan group only (p 5 0.03).
Ejection fraction. No differences in mean change in LVEF
were observed among the different treatment groups (p 5
0.75). The LVEF at week 12 was significantly different from
that at baseline in the 50-mg losartan group only (p 5 0.02).
Signs and symptoms of heart failure. The clinical status of
each patient was assessed with regard to dyspnea, paroxysmal
nocturnal dyspnea, orthopnea, jugular venous pressure, pe-
ripheral edema, pulmonary rales, third heart sound and func-
tional class. As shown in Table 4, no statistically significant
differences among the treatment groups were observed in the
distribution of patients with regard to any of these variables.
Functional class improved in 19 patients (16%), evenly distrib-
uted among the treatment groups. Table 4 shows the incidence
of worsening of the signs and symptoms of heart failure at the
end of the double-blind period. No statistically significant
differences were noted among the treatment groups in the
proportion of patients (25 mg of losartan, n 5 5 [13.2%]; 50 mg
of losartan, n 5 3 [7.5%]; 20 mg of enalapril, n 5 2 [5.3%])
satisfying the prospective definition of worsening heart failure.
Subgroup analyses were performed based on age, gender,
race, LVEF and functional class. The effect of each of these
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factors on walk distance and treadmill exercise duration was
evaluated by performing an analysis of covariance with treat-
ment, investigator and subgroup as factors and baseline walk
distance or treadmill exercise duration as a covariate. No
treatment by subgroup interactions were significant for any of
the subgroups considered.
Safety and tolerance. The safety profile of losartan was
evaluated in terms of the incidence of clinical and laboratory
adverse experiences. Adverse clinical experiences led to dis-
continuation of the trial in only one patient from each of the
treatment groups. Clinical adverse experiences were reported
in 25 patients of the 25-mg losartan group (65.8%); in 27
(67.5%) of the 50-mg losartan group and in 23 (60.5%) of the
20-mg enalapril group. The most common adverse clinical
experiences reported were dyspnea, worsening heart failure,
dizziness and infection of the upper respiratory tract. A total of
six deaths were reported during the double-blind period of the
study. One death (due to ventricular tachycardia) occurred in
the 25-mg losartan group, whereas five deaths (one death each
due to sudden death, worsening heart failure, ventricular
arrhythmia and septicemia and one death of unknown cause)
were reported in the 50-mg losartan group. There were no
deaths reported in the enalapril group. None of these deaths
were considered related to study drug therapy.
Table 1. Baseline Patient Characteristics
L25
(n 5 38)
L50
(n 5 40)
E20
(n 5 38)
Total
(n 5 116)
Gender
Female 6 (16%) 11 (28%) 9 (24%) 26 (22%)
Male 32 (84%) 29 (73%) 29 (76%) 90 (78%)
Age (yr)
Mean 6 SD 57.4 6 11.3 56.3 6 16.2 59.7 6 11.5 57.8 6 13.2
Range (28–80) (25–83) (33–81) (25–83)
Racial origin
White 27 (71%) 26 (65%) 29 (76%) 82 (71%)
Oriental 1 (3%) 1 (3%) 1 (3%) 3 (3%)
Black 9 (24%) 11 (28%) 5 (13%) 25 (22%)
Hispanic 1 (3%) 2 (5%) 3 (8%) 6 (5%)
Duration of primary diagnosis (yr)
,1 11 (29%) 4 (10%) 8 (21%) 23 (20%)
1–5 18 (47%) 25 (63%) 16 (42%) 59 (51%)
5.01–10 7 (18%) 5 (13%) 8 (21%) 20 (17%)
.10 2 (5%) 6 (15%) 6 (16%) 14 (12%)
Mean 6 SD 3.4 6 3.2 4.5 6 4.4 5.3 6 6.2 4.4 6 4.8
Range 0.33–13 0.5–20 0.33–35 0.33–35
Etiology of heart failure
Ischemic heart disease 18 (47%) 19 (48%) 18 (47%) 55 (47%)
Dilated cardiomyopathy 13 (34%) 16 (40%) 19 (50%) 48 (41%)
Arterial hypertension 4 (11%) 1 (3%) 0 5 (4%)
Valvular heart disease 2 (5%) 1 (3%) 1 (3%) 4 (3%)
Ischemic cardiomyopathy 0 1 (3%) 0 1 (1%)
Idiopathic etiology 0 1 (3%) 0 1 (1%)
Alcoholic cardiomyopathy 0 1 (3%) 0 1 (1%)
Ethanol abuse 1 (3%) 0 0 1 (1%)
NYHA functional class
II 20 (53%) 22 (55%) 13 (34%) 55 (47%)
III 18 (47%) 16 (40%) 25 (66%) 59 (51%)
IV 0 2 (5%) 0 2 (2%)
There were no statistically significant differences among the treatment groups. L25 5 losartan, 25 mg; L50 5 losartan,
50 mg; E20 5 enalapril, 20 mg; NYHA 5 New York Heart Association.
Table 2. Previous Cardiovascular Therapies by Drug Class*
L25
(n 5 38)
L50
(n 5 40)
E20
(n 5 38)
ACE inhibitors 38 (100.0) 40 (100.0) 38 (100.0)
Antiarrhythmic agents 4 (10.5) 9 (22.5) 8 (21.1)
Anticoagulant agents† 24 (63.2) 27 (67.5) 23 (60.5)
Beta-blockers 4 (10.5) 1 (2.5) 3 (7.9)
Calcium channel blockers 1 (2.6) 4 (10.0) 3 (7.9)
Digitalis 31 (81.6) 34 (85.0) 33 (86.8)
Diuretic agents 38 (100.0) 40 (100.0) 37 (97.4)
Other vasodilators 13‡ (34.2) 22 (55.0) 23 (60.5)
*This table contains counts of patients. If a patient had multiple concomitant
therapies within a particular therapy group, the patient was only counted once in
the therapy group total. †Aspirin is included in the category of anticoagulant
agents. The number of patients taking aspirin was 33. ‡Statistically significant
difference between the 25-mg losartan and 20-mg enalapril groups, p , 0.05.
Data are presented as number (%) of patients. ACE 5 angiotensin-converting
enzyme; other abbreviations as in Table 1.
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Sixteen percent (6 of 38) of the patients in the 25-mg
losartan group, 25% (10 of 40) of those in the 50-mg losartan
group and 11% (4 of 37) of those in the enalapril group had at
least one laboratory adverse experience. Eight percent (3 of
38) of the patients in the 25-mg losartan group, 10% (4 of 40)
in the 50-mg losartan group and 5% (2 of 37) of those in the
enalapril group had a laboratory adverse experience that was
considered drug related.
Laboratory screening (Table 5) revealed no significant
intragroup or intergroup differences at 12 weeks for blood urea
nitrogen, serum potassium, serum sodium or serum uric acid.
The mean changes in serum creatinine were negligible in both
losartan groups, whereas the increase from baseline of 0.08 6
0.15 mg/dl in the enalapril group was significant (p , 0.05); this
increase was also significant against the 50-mg losartan change
(20.02 mg/dl).
Discussion
The present study was designed to test the following
hypotheses: 1) 12-week oral administration of losartan, an
angiotensin II receptor antagonist, to patients with heart
failure will be well tolerated; and 2) functional capacity and
clinical status will be similar in patients with heart failure after
oral administration for 12 weeks of either losartan or enalapril.
In addition, this study was designed to gain experience in the
conversion of therapy from an ACE inhibitor to losartan.
Interpreting the results of the current study. There were
no significant differences in the demographics and heart failure
characteristics among the different treatment groups at base-
line. All patients were withdrawn from ACE inhibitor therapy
at the initiation of active study therapy, and most patients were
titrated to their expected dose level in each treatment group.
The major variables evaluated as indicators of treatment
efficacy were functional capacity and clinical status assessed by
treadmill exercise time, 6-min walk test distance, dyspnea-
fatigue index, LVEF, signs and symptoms of heart failure and
functional class. Because the patients in this study had been
previously treated with an ACE inhibitor, exercise capacity was
not expected to change significantly during the study, unless
treatment with losartan was not effective. The data revealed
that exercise duration at the end of the study was increased
from baseline in all treatment groups. This increase was
significant in the enalapril group (p 5 0.03) and marginally
significant in the 50-mg losartan group (p 5 0.06). However,
the increases in exercise duration were small and not signifi-
cantly different among the treatment groups. The distance
traversed in the 6-min walk test was also not significantly
different among any of the treatment groups. Thus, exercise
capacity appeared to be similar in patients treated with either
25 mg of losartan once daily, 50 mg of losartan once daily or
10 mg of enalapril twice daily for 12 weeks after discontinua-
tion of open-label ACE inhibitors.
Consistent with the exercise results, the dyspnea-fatigue
index and LVEF measurements showed no differences in mean
changes among the treatment groups. Although there were no
differences in mean changes among treatment groups, there
was a significant improvement in the dyspnea-fatigue index in
Table 3. Results of Variables Used to Assess Efficacy of Treatment
Results Drug Baseline Treatment Change Mean Change
p Values
Intergroup Comparison
Intragroup
Comparisons
Versus Group
B
Versus Group
C
Walk test (m) L25 (A) 383 6 75 393 6 101 9 6 48 2.3% 0.69 0.50 0.07
L50 (B) 394 6 71 397 6 102 3 6 71 0.7% — 0.78 0.73
E20 (C) 393 6 79 393 6 101 0 6 63 0% — — 0.74
Intergroup test results for change 0.79
Treadmill test (s) L25 (A) 560 6 151 597 6 192 37 6 135 6.6% 0.96 0.65 0.28
L50 (B) 547 6 155 584 6 206 37 6 119 6.7% — 0.60 0.06
E20 (C) 519 6 179 568 6 198 49 6 123 9.4% — — 0.03
Intergroup test results for change 0.85
Dyspnea fatigue index L25 (A) 6.2 6 2.3 6.6 6 2.2 0.4 6 1.5 0.94 0.75 0.03
L50 (B) 6.1 6 2.4 6.4 6 2.6 0.3 6 1.7 — 0.70 1.00
E20 (C) 5.8 6 2.3 6.3 6 2.4 0.5 6 1.7 — — 0.30
Intergroup test results for change 0.92
LVEF (%) L25 (A) 26.4 6 10.1 28.2 6 12.0 1.8 6 7.2 0.60 0.86 0.51
L50 (B) 25.4 6 10.7 27.7 6 11.4 2.3 6 4.4 — 0.47 0.02
E20 (C) 24.6 6 7.9 26.1 6 10.2 1.5 6 6.8 — — 0.17
Intergroup test results for change 0.75
JVD at 45° L25 (A) 4.3 6 4.3 3.9 6 3.9 20.3 6 2.2 0.25 0.59 0.29
L50 (B) 3.2 6 3.9 3.9 6 5.7 0.7 6 4.1 — 0.53 1.00
E20 (C) 3.5 6 3.9 3.7 6 4.1 0.2 6 1.9 — — 0.29
Intergroup test results for change 0.52
Data are presented as mean value 6 SD. JVD 5 jugular venous distention; LVEF 5 left ventricular ejection fraction; other abbreviations as in Table 1.
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the 25-mg losartan treatment group (p 5 0.03) and a signifi-
cant improvement in ejection fraction in the 50-mg losartan
treatment group (p 5 0.02) when compared with baseline. No
statistically significant intergroup differences were observed in
the signs and symptoms of heart failure with regard to the
distribution of the patients at the end of the double-blind
period.
With respect to safety, a comparable incidence of overall
clinical adverse experiences, serious adverse experiences,
hypotension-related symptoms and worsening heart failure was
observed among all the treatment groups. Unexpectedly, five
deaths occurred in the 50-mg losartan treatment group com-
pared with one and none in the 25-mg losartan and 20-mg
enalapril treatment groups, respectively. Of these five deaths in
the 50-mg losartan treatment group, one occurred as a result of
cholecystitis and sepsis and another occurred in a noncompli-
ant patient who apparently had not been taking losartan for 11
days before death, based on the amount of study drug found in
the patient’s body after death. Hence, three deaths remain
unexplained. None of these deaths were considered by the
treating physician to be related to study drug therapy. The
apparent increase in mortality in the 50-mg losartan group in
this study may be a result of chance related to the use of
multiple treatment groups with a small sample size, because
such an increase in mortality was not observed in the 25-mg
losartan group in this study and was not observed after losartan
treatment in two other studies in patients with heart failure. In
the hemodynamic study reported by Crozier et al. (10), 29, 22
and 26 patients with symptomatic heart failure and baseline
pulmonary capillary wedge pressure $13 mm Hg received
25 mg of losartan, 50 mg of losartan or placebo, respectively,
for 12 weeks. The use of ACE inhibitors was not allowed
Table 4. Clinical Status Assessment at End of Study
Clinical Assessment Group
Treatment Effect
Comparison
(p values)
Worse
No
Change Improvement
Versus Group
B
Versus Group
C
Exertional dyspnea L25 (A) 3 (7.8%) 24 (63.1%) 11 (28.9%) 0.96 0.94
L50 (B) 4 (10.0%) 25 (62.5%) 11 (27.5%) — 0.862
E20 (C) 3 (7.8%) 24 (63.1%) 11 (28.9%) — —
Paroxysmal nocturnal L25 (A) 0 (0.0%) 36 (94.7%) 2 (5.2%) 0.88 0.46
dyspnea L50 (B) 1 (2.5%) 34 (85.0%) 5 (12.5%) — 0.41
E20 (C) 1 (2.6%) 35 (92.1%) 2 (5.2%) — —
Orthopnea L25 (A) 6 (15.7%) 28 (73.6%) 4 (10.5%) 0.95 0.42
L50 (B) 4 (10.0%) 31 (77.5%) 5 (12.5%) — 0.24
E20 (C) 2 (5.2%) 32 (84.2%) 4 (10.5%) — —
Edema L25 (A) 3 (7.8%) 28 (73.6%) 7 (18.4%) 0.10 0.75
L50 (B) 6 (15.0%) 30 (75.0%) 4 (10.0%) — 0.21
E20 (C) 2 (5.2%) 32 (84.2%) 4 (10.5%) — —
Rales L25 (A) 0 (0.0%) 37 (97.3%) 1 (2.6%) 0.12 *
L50 (B) 2 (5.0%) 37 (92.5%) 1 (2.5%) — 0.16
E20 (C) 0 (0.0%) 38 (100%) 0 (0.0%) — —
Third heart sound L25 (A) 3 (7.8%) 31 (81.5%) 4 (10.5%) 0.87 0.41
L50 (B) 2 (5.0%) 33 (82.5%) 5 (12.5%) — 0.21
E20 (C) 2 (5.2%) 35 (92.1%) 1 (2.6%) — —
NYHA functional L25 (A) 2 (5.2%) 30 (78.9%) 6 (15.7%) 0.99 0.87
class L50 (B) 0 (0.0%) 34 (85.0%) 6 (15.0%) — 0.84
E20 (C) 2 (5.2%) 29 (76.3%) 7 (18.4%) — —
*Value could not be computed because the covariance matrix is singular. Data are presented as number (%) of
patients. Abbreviations as in Table 1.
Table 5. Laboratory Results in Three Treatment Groups
L25
(n 5 35*)
L50
(n 5 35*)
E20
(n 5 35*)
Serum creatinine (mg/dl)
Baseline values 1.25 6 0.25 1.24 6 0.33 1.30 6 0.37
Change at 12 weeks 0.02 6 0.14 0.02 6 0.28† 0.08 6 0.15‡
Blood urea nitrogen
Baseline values 19.8 6 7.2 17.6 6 6.6 22.1 6 10.3
Change at 12 weeks 20.5 6 5.1 1.1 6 7.4 3.5 6 9.2
Serum potassium (mEq/liter)
Baseline values 4.38 6 0.44 4.25 6 0.48 4.44 6 0.47
Change at 12 weeks 20.16 6 0.43 0.12 6 0.42 20.05 6 0.47
Serum sodium (mEq/liter)
Baseline values 138.7 6 2.9 139.0 6 2.7 138.1 6 2.9
Change at 12 weeks 1.2 6 5.3 0.2 6 3.0 20.3 6 3.6
Serum uric acid (mg/dl)
Baseline values 7.45 6 1.59 7.33 6 1.91 7.37 6 2.31
Change at 12 weeks 20.17 6 1.68 20.03 6 0.97 0.06 6 1.09
*Minimal sample size for each variable. †Statistically significant difference
compared with 20-mg enalapril group, p , 0.05. ‡Statistically significant within-
group difference, p , 0.05. Data are presented as mean value 6 SD. Abbrevi-
ations as in Table 1.
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during the treatment period. No patient died in any of the
three treatment groups during the 12 weeks of the study.
Dickstein et al. (18) recently reported the results of a study
very similar in design to the present study. In that trial, patients
in functional class III or IV heart failure, most of whom had
been previously treated with ACE inhibitors, were randomized
to double-blind treatment with 25 mg of losartan every day
(n 5 52), 50 mg of losartan every day (n 5 56) or 10 mg of
enalapril twice daily (n 5 58) for 8 weeks. All open-label ACE
inhibitors were discontinued before randomization, as was
done in the present study. During the 8-week treatment period,
zero, two and two patients died in the 25-mg losartan, 50-mg
losartan and enalapril treatment groups, respectively. Thus,
with the exception of the 50-mg losartan treatment group in
this study, the mortality rate observed after treatment with
25 mg of losartan every day or 50 mg of losartan every day
appears to be low and comparable to the control agent used in
the trials. These findings support the interpretation that the
mortality difference observed in this study was likely due to
chance occurrence related to the use of multiple treatment
groups with a small sample size in study design. Moreover,
recently published studies further support this interpretation.
The Evaluation of Losartan In The Elderly (ELITE) study
demonstrated that treatment with losartan was associated with
less all-cause mortality than treatment with captopril, a drug
known to have survival benefits (19). Similarly, an improve-
ment in survival with losartan of similar magnitude to that seen
in the ELITE study has been recently observed in two placebo-
controlled, 12-week exercise studies involving 736 patients with
symptomatic heart failure (20). In these studies, losartan did
not improve treadmill exercise time compared with placebo
(the primary end point) but was associated with an unexpected
reduction in mortality. All the available data indicate that a
trial designed to determine the effects of angiotensin II recep-
tor blockade on mortality in patients with symptomatic heart
failure deserves further study and is ethically responsible.
The incidence of nonfatal serious adverse experiences and
worsening heart failure symptoms were comparable among the
groups. No unexpected serious adverse experiences were re-
ported. Laboratory experience showed no statistically signifi-
cant differences among the treatment groups, with the excep-
tion that the mean changes in serum creatinine from baseline
were negligible in both losartan groups, whereas a small increase
in creatinine levels was observed in the enalapril group.
Exercise capacity was also evaluated in the study reported
by Dickstein et al. (18), which shared a similar study design to
that of the present trial. The findings of that study were similar
to ours in that no significant intergroup differences were noted
with respect to exercise capacity (6-min walk test), clinical
status (dyspnea-fatigue index) or incidence of adverse clinical
experiences (18). Both of these studies found that losartan was
generally well tolerated in the short-term treatment of mild to
severe heart failure and that no difference in exercise capacity
was observed after treatment with 25 mg of losartan every day,
50 mg of losartan every day or 10 mg of enalapril twice daily for
8 or 12 weeks.
Potential advantages of losartan over nonspecific ACE
inhibition. In contrast to losartan, ACE inhibitors interfere
with the cleavage not only of angiotensin I, but also of
bradykinins, enkephalins and substance P (13,14,21–23). As
previously stated, accumulation of these substances is thought
to be responsible for the ACE inhibitor–associated side effects
of cough and hypotension. In keeping with these observations,
a large clinical trial in hypertensive patients recently demon-
strated that the incidence of cough with losartan was signifi-
cantly less than that observed with lisinopril and similar to that
noted with hydrochlorothiazide (21). Because all the patients
recruited into the current study had previously been success-
fully treated with an ACE inhibitor (thus eliminating patients
intolerant to ACE inhibitors), it is not surprising that the
beneficial effect of cough reduction was not evident.
Administration of an ACE inhibitor is associated with a
decrease in renal filtration fraction (24). Kon et al. (25)
observed a decrease in glomerular filtration fraction with ACE
inhibition, which can be prevented by administration of the
bradykinin antagonist HOE 140. Bradykinin induced by ACE
inhibition could lead to efferent arteriolar dilation and de-
creased renal perfusion pressure. Losartan, which does not
cause bradykinin accumulation, has been shown to raise serum
creatinine less than the level previously reported with ACE
inhibitors in hypertensive patients (21,26). In addition, hyper-
kalemia or hyperuricemia have not been found to be a
significant problem in trials using losartan (21,26). In this
respect, the results of the laboratory data observed in our study
support these observations. Specifically, the mean change from
baseline in serum creatinine levels was negligible in both
losartan groups, whereas an increase was noted in the enalapril
group, compared with both baseline values and losartan. In the
study of Dickstein et al. (18), which, as mentioned earlier,
enrolled patients with severe heart failure, the serum potas-
sium and blood urea nitrogen values, in addition to serum
creatinine, also decreased after 8 weeks of treatment in both
losartan groups, compared with the enalapril group.
Finally, ACE inhibitor therapy may be associated, at times,
with first-dose hypotension (27). This situation is most com-
monly encountered in patients with hyponatremia, hypovole-
mia, low baseline blood pressure, renal impairment and high
baseline levels of renin or aldosterone (2,3). Potentiation of
the vasodilator effects of bradykinins and prostaglandins ap-
pears to contribute to the first-dose hypotension associated
with ACE inhibitor therapy (28,29). Accordingly, losartan,
which does not interfere with the degradation of these pep-
tides, should theoretically result in fewer episodes of first-dose
hypotension. In this study, supine and standing blood pressures
and pulses were monitored at hourly intervals for 5 h after
receiving the initial doses of either losartan (12.5 mg) or
enalapril (2.5 mg) and after each titration. Mean changes from
baseline for these measurements were small and clinically
nonsignificant. No unusual trends associated with a particular
treatment were evident from the results.
Study limitations. The fact that all the patients in this study
were treated with ACE inhibitors before enrollment intro-
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duced a bias into the study because patients who tolerated
ACE inhibitor therapy were preselected and the incidence of
side effects was minimized (i.e., cough and first-dose hypoten-
sion), side effects which might have been otherwise encoun-
tered. The long-term effects of the previous ACE inhibitor
therapy might have been partially operative for a period after
randomization to losartan. Nonetheless, a 12-week trial such as
ours should have been of adequate length to detect a deteri-
oration in the clinical status of the patients if treatment with
losartan was inefficacious. In previous studies, clinical deteri-
oration became evident 3 and 6 weeks after cessation of
therapy with quinapril or enalapril, respectively (30,31). Al-
though the greatest hemodynamic effects were observed with
the 50-mg dose of losartan, our study did not clarify the
optimal dose of losartan for long-term therapy in patients with
heart failure. No obvious differences were noted between the
25- or 50-mg dose of losartan. It is possible that the magnitude
of the hemodynamic effect will not translate into differences in
clinical outcome, because negative neurohormonal feedback
mechanisms may have attenuated potential beneficial re-
sponses associated with the greater hemodynamic change.
Losartan is a specific angiotensin I receptor blocker and does
not inhibit the angiotensin II receptor subtype. Because there
is no known physiologic effect of angiotensin II receptor
stimulation in adults, the effect of long-term, unopposed
angiotensin II receptor stimulation associated with losartan
treatment is unknown.
Data do not currently exist on the long-term effects of
losartan on clinical end points such as mortality or hospital
stays of patients with heart failure. Evaluation of the long-term
clinical effects of losartan, alone or in combination with an
ACE inhibitor, in patients with heart failure requires further
studies.
Conclusions. The results of this study demonstrate that
losartan, a novel angiotensin II receptor antagonist, is gener-
ally well tolerated in patients with symptomatic heart failure
previously treated with ACE inhibitors. Similar effects on
functional capacity and clinical status were observed after 12
weeks of once-daily dosing of 25 mg of losartan, or 50 mg of
losartan or twice-daily dosing of 10 mg of enalapril. A signif-
icant difference in clinical or exercise effects between the
25-mg losartan and 50-mg losartan doses was not observed
after 12 weeks of once-daily dosing. This study supports further
investigation of losartan for the treatment of patients with
heart failure.
We thank Renata Bergunder for expert secretarial assistance.
Appendix
Principal Investigators for the Losartan Pilot
Exercise Study
Michael R. Bristow, MD, PhD, University of Colorado, Health Science Center,
Denver, Colorado; Harry Colfer, MD, Burns Clinic, Petoskey, Michigan; Uri
Elkayam, MD, FACC, University of Southern California School of Medicine, Los
Angeles, California; Ray E. Hershberger, MD, University of Oregon, Health
Science Center, Portland, Oregon; Michael B. Higginbotham, MD, Duke University
Medical Center, Durham, North Carolina; Bruce Jackson, MD, Redondo Beach,
California; Philip Kirlin, MD, Methodist Hospital, Indianapolis, Indiana; Daniel
Krauss, MD, FACC, Roberto M. Lang, MD, FACC, University of Chicago
Medical Center, Chicago, Illinois; Ileana L. Pina, MD, Temple University Hospital,
Philadelphia, Pennsylvania; Hillel S. Ribner, MD, Newark Beth Israel Medical
Center, Newark, New Jersey; John J. Smith, MD, New England Medical Center,
Boston, Massachusetts; Douglas E. Vaughan, MD, FACC, West Roxbury Veterans
Affairs Medical Center, West Roxbury, Massachusetts; John Wilson, MD, Hospital
of the University of Pennsylvania, Philadelphia, Pennsylvania; Laurence G. Yellen,
MD, San Diego, California; James B. Young, MD, The Methodist Hospital, Baylor
College of Medicine, Houston, Texas; Salim Yusuf, MD, Robert S. McKelvie, MD,
Hamilton General Hospital, Hamilton, Ontario, Canada
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